PLACEBO-CONTROLLED TRIAL OF TOPICAL INTERFERON IN LABIAL AND GENITAL HERPES

Marek Glezerman, Vered Cohen, Moshe Movshovitz, Jacob Shoham, Eitan Lunenfeld, Israel Sarov, Thomas Doerner, Michel Revel

Research output: Contribution to journalArticlepeer-review

38 Scopus citations

Abstract

The efficacy of topical interferon-β (IFN-β) treatment was assessed in 25 patients with herpes of the lips or genitals who completed a 2-year follow-up in a double-blind placebo-controlled trial. IFN-β gel (105 U/g) 4 times daily (about 2 × 104 U) applied locally during eruptions (about 10 days) reduced the mean number of recurrences (p<0·007) and the duration of eruptions (p <0·007): in the placebo group these indices did not change significantly. Reduction of symptoms and severity was noted in 11 of 12 patients on IFN-β and in only 1 on placebo. No important side-effects were recorded. Topical IFN-β may therefore be advantageous as a time-limited local treatment of recurrent herpes simplex virus infections of the genitals and lips.

Original languageEnglish
Pages (from-to)150-152
Number of pages3
JournalThe Lancet
Volume331
Issue number8578
DOIs
StatePublished - 23 Jan 1988
Externally publishedYes

ASJC Scopus subject areas

  • General Medicine

Fingerprint

Dive into the research topics of 'PLACEBO-CONTROLLED TRIAL OF TOPICAL INTERFERON IN LABIAL AND GENITAL HERPES'. Together they form a unique fingerprint.

Cite this